Corcept Therapeutics Incorporated (CORT) — Fair Value Analysis

Base-case fair value (P50): $77.62 · Current price: $84.17 · Verdict: Fairly Valued

The Verdict on CORT

Based on our Monte Carlo simulations, CORCEPT THERAPEUTICS INC (CORT) is currently deemed Fairly Valued. While the current market price of $84.17 presents an -7.8% gap relative to our median fair value (P50) of $77.62, this deviation falls within the expected range for a stock with an average quality tier. Our analysis suggests that CORT is trading largely in line with its intrinsic value, with a balanced outlook considering various forward-looking scenarios.

How CORT stacks up against peers

CORT's operational and financial health is categorized as average, indicating a solid but not exceptional standing within its sector (n/a). This average quality tier supports the Monte Carlo simulations' finding that the stock is Fairly Valued at $84.17. Companies in this tier often exhibit a reasonable balance of growth, profitability, and risk, making significant undervaluation or overvaluation less common unless specific catalysts or headwinds emerge. The P50 fair value of $77.62 reflects this balanced profile, suggesting that the market's current assessment of $84.17 is largely accurate.

What this means for investors

For investors considering CORT, the Fairly Valued verdict at $84.17 and an -7.8% relative to the $77.62 P50 fair value implies that immediate, compelling mispricing opportunities are limited based on our quantitative models. While a downside scenario is always possible, the average quality tier suggests a degree of resilience. Conversely, a bull case would rely on the company outperforming current projections. To fully understand the range of potential outcomes, including the P10 bear-case and P90 bull-case distributions, and to track CORT's fair value as new fundamentals are released, sign up for a free FairCurve account.